The treatment of hepatitis C is a therapeutic challenge in renal transplant recipients. Interferon based regimens are relatively contraindicated due to their side effects and high risk of graft failure. With the availability of direct antivirals the situation has changed now and sustained virological response (SVR)\u3e90% had been achieved in patients with normal kidney function. There is limited data available on the safety of these agents in renal transplant recipients. Here we report a case of a kidney transplant recipient with Hepatitis C genotype 3 infections successfully treated with Sofosbuvir and Daclatasvir based regimen. This is the first reported case from Pakistan